Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | HRAS | P01112 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441974 | 0.93 | ERBB2 (0.43) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL3417386 | 0.93 | ERBB2 (0.43) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL14878102 | 0.90 | HDAC1 (0.40) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL3417370 | 0.90 | HDAC1 (0.39) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL30125562 | 0.88 | HDAC1 (0.51) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL16710975 | 0.88 | CYP17A1 (0.43) | HDAC1HDAC2HDAC8GSK3BDYRK1A | |
| SCHEMBL3417244 | 0.87 | HDAC1 (0.42) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL3934001 | 0.87 | HDAC1 (0.42) | HDAC1HDAC2HDAC8ERBB2GSK3B | |
| SCHEMBL13845563 | 0.87 | HDAC1 (0.49) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL19614861 | 0.87 | ERBB2 (0.41) | HDAC1HDAC2HDAC8ERBB2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | DESIGN THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4460302-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2024-04-18 | — | — | US | disclosed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108727407-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2393362-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | Immunogen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, CDR2 | HDAC1 721/4885HDAC2 1141/4885HDAC8 196/4885 |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC1 849/4885HDAC2 719/4885HDAC8 1313/4885 |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | HDAC1 489/4885HDAC2 551/4885HDAC8 156/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | HDAC1 849/4885HDAC2 719/4885HDAC8 1313/4885 |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, ATXN10 | HDAC1 569/4885HDAC2 1062/4885HDAC8 202/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | HDAC1 935/4885HDAC2 795/4885HDAC8 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.